I'd like to add two comments. First, Professor Evenett mentioned the example of South Korea. While I largely agree that South Korea hasn't been able to vaccinate as many people as some other countries have, SK Bioscience in South Korea is indeed a manufacturer of AstraZeneca's vaccine and will be a manufacturer of Novavax's vaccine when that is approved, so the investments that South Korea has made have yielded some benefits. We cannot completely write them off. That's the first point.
The second is that, given what we've seen around trade and export controls, if we assume a state of the future that will not let this happen again, and if we have a global treaty that prevents this from happening, then perhaps we don't need to think about every country looking at domestic manufacturing.
If we assume that future scenario will still have similar kinds of export controls, the important consideration becomes, if Canada or any country thinks about having a domestic manufacturing side—a contract manufacturing type—then how does that case remain sustainable so that the manufacturing plant is not only serving the needs during a pandemic but has a steady demand to supply something that is required during routine times? As Professor Evenett said, it must be flexible so that it can switch from one vaccine platform to another, or one vaccine type to another, so that its overall demand remains sustainable.
Those would be areas to examine when you think about domestic manufacturing.